The Association between Blood Indexes and Immune Cell Concentrations in the Primary Tumor Microenvironment Predicting Survival of Immunotherapy in Gastric Cancer

Jiajia Yuan 1,†, Xingwang Zhao 1,†, Yanyan Li 1, Qian Yao 2, Lei Jiang 1, Xujiao Feng 1, Lin Shen 1, Yilin Li 1,* and Yang Chen 1,*

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, China; jyuan@bjmu.edu.cn (J.Y.); zhaoxingwang237@163.com (X.Z.); qiuyesyu3@163.com (Y.L.); ncuskjianglei@163.com (L.J.); 13293656798@163.com (X.F.); shenlin@bjmu.edu.cn (L.S.)

2 Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, China; yaoqian@bjmu.edu.cn

* Correspondence: liyilin@bjcancer.org (Y.L.); yang_chen@bjcancer.org (Y.C.);
Tel.: +86-010-88196747 (Y.L. & Y.C.)

† These authors contributed equally to this work.

Simple Summary: Due to the complexity of the immune response, no single biomarker is available for adequate patient stratification in the context of gastric cancer (GC). In this study, we used multiplexed immunohistochemistry combined with digital image analysis to uncover the immune cell features in 80 patients with GC. Furthermore, we analyzed the association of blood indexes with the primary gastric cancer immune microenvironment. Then, we validated the predicted value of the blood index in a larger GC cohort (n = 357) receiving anti-PD-1/PD-L1 immunotherapy. Importantly, this approach allowed us to map rare cell types with complex phenotypes, characterize the PD-1 and PD-L1 expression intensity in situ, and assess the biomarker value of these parameters and their associations with the blood index. Our data suggest that blood indexes, associated with primary tumor microenvironment, can be used to predict the immune related prognosis in GC.

Abstract: The tumor microenvironment plays a vital role in tumor progression and treatment response. However, the association between immune cell concentrations in primary tumor and blood indexes remains unknown. Thus, we enrolled patients with gastric cancer (GC) in two cohorts. We used multiplexed immunohistochemistry to quantify in situ proteins covering rare cell types at sub-cellular resolution in 80 patients with GC in the first cohort. A high correlation between the LMR (lymphocyte-to-monocyte ratio)/NLR (neutrophil-to-lymphocyte ratio) and tumor immune microenvironment was found. The density of exhausted CD8 T cells including CD8+PD1−TIM3+, CD8+LAG3+PD1−, CD8+LAG3+PD1+TIM3− was negatively associated with LMR and positively associated with NLR (p < 0.05). Additionally, the higher density of macrophages in tumor core was associated with a higher platelet-to-lymphocyte ratio and systemic immune-inflammation index. Furthermore, we validated the prognostic value of LMR and NLR in an independent cohort of 357 gastric cancer patients receiving immunotherapy. Higher LMR at baseline was significantly associated with superior immune-related PFS (irPFS) and a trend of superior immune-related OS (irOS). Higher NLR was associated with inferior irOS. In conclusion, blood indexes were associated with immune cells infiltrating in primary tumors of GC. NLR and LMR are associated with the density of exhausted CD8+ T immune cells, which leads to prognostic values of immunotherapy.

Keywords: gastric cancer; immunotherapy; PD-1/PD-L1; tumor microenvironment; blood index
1. Introduction

Gastric cancer (GC), with high incidence and death rates in China and worldwide, remains a major threat to public health [1]. Immunotherapy has become a standard for first-line and later-line therapy of GC [2]. CheckMate 649, a phase 3 clinical trial comparing immunotherapy plus chemotherapy versus chemotherapy alone, suggested nivolumab plus chemotherapy resulted in significant improvements in OS, with PD-L1 CPS of one or more and PFS with PD-L1 CPS of five or more [3]. However, the response rate for the general population of GC patients with immunotherapy is 60%, 15% higher than chemotherapy alone, which is far from enough. Although the PD-L1 CPS score suggested a higher score may give a high response rate, other biomarkers for response prediction are urgently needed [4].

The tumor microenvironment, including tumor immune cells such as T cells, B cells, neutrophils and macrophages, and their precise location in relation to cancer cells, may influence the therapeutic response [5]. Immunohistochemistry has been widely used to analyze immune cells in patients with GC, such as CD3, CD8, PD-1, PD-L1, CD163, and LAG3 expression [6–9]. However, traditional immunohistochemistry only stained one marker in one slide and could not identify rare cell types with the combination of several markers. Thus, multiplexed immunohistochemistry (m-IHC), which can simultaneously detect multiple antigens in situ with single cell resolution, has been developed [10].

Studies from our team have suggested that blood indexes including CD4$^+$ T lymphocytes are related to the response to immunotherapy in gastrointestinal cancer [11]. Moreover, the lymphocyte-to-monocyte ratio (LMR) serves as an independent prognostic factor for GC patients treated with ICIIs [12]. However, the relationships of blood index and the primary tumor microenvironment were largely unknown. Hence, in order to elucidate the relationship between immune cell concentrations and verify the prognostic factors of blood index, we studied two independent retrospective cohorts of GC. In the first cohort, we examined the relationship between immune cells in primary tumor and blood indexes. In the second cohort, we validated the prognostic value of blood index in GC patients receiving immunotherapy.

2. Materials and Methods

2.1. Study Population

We performed a tumor immune microenvironment evaluation of 80 GC patients enrolled at Peking University Cancer Hospital and Institute from July 2014 to December 2019, comprising the first cohort. An independent validation cohort included 357 GC patients receiving anti-PD-1/PD-L1 based therapy between November 2016 and May 2021 at Peking University Cancer Hospital was established. Written informed consent was signed by the patients or their legal guardians before immunotherapy. All blood tests and treatments were performed in accordance with institutional guidelines. Clinical data collected from patients’ electronic medical records included demographic information, histology, and laboratory tests results. The inclusion criteria for the validation cohort were: (1) pathologically confirmed GC; (2) administration of anti-PD-1/PD-L1-based treatment regimens. The exclusion criteria were: (1) incomplete hematological data; (2) lost follow-up.

Patients were observed until death or end of follow-up (5 June 2021), whichever came first. Dates of death were obtained through telephone call-based follow-up by doctors or the follow-up center in our hospital. The study protocol was approved by the Ethics Committee of the Peking University Cancer Hospital and Institute.

2.2. Assessment of Tumor Microenvironment

Multiplexed immunohistochemistry (m-IHC) staining was performed to visualize the expression of CD8, PD-1, TIM3, LAG3, CD4, FoxP3, CTLA4, PD-L1, CD68, CD163, HLADR, STING, CD20, CD66b, CLDN18.2 and CD147. Tissues, within 30 min after being excised, were fixed in formalin for 24–48 h, dehydrated and embedded in paraffin, then cut into sections with a thickness of 4 µm. FFPE slides were melted and dehydrated at...
60 °C for 12 h, deparaffinized and rehydrated using xylene and alcohol, and then placed in citrate buffer (pH 6.0) for FoxP3 staining or EDTA buffer (pH 9.0) for others, and the whole reactive system was placed in a microwave oven for heat-induced antigen retrieval. Then, the sections were blocked by a commercially available blocking buffer (X0909; Dako, Santa Clara, CA, USA) for 10 min. Supplementary Table S1 shows the antibodies used for the staining. The slides were incubated with the primary antibody and horseradish peroxidase-conjugated secondary antibody, and tyramine signal amplification (TSA) was performed in accordance with the pre-optimized antibody concentration and the order of staining. Antibody stripping and antigen retrieval were performed after each round of TSA. 4′, 6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich, St. Louis, MO, USA; cat. D9542) was used to stain nuclei. All stained GC specimens were evaluated by two experienced pathologists to ensure that they met the requirements for further analysis.

Images were acquired using the Mantra Quantitative Pathology Imaging System (PerkinElmer, Waltham, MA, USA). A whole slide scan of the multiplex tissue sections produced multispectral fluorescent images visualized in Phenochart (PerkinElmer, Waltham, MA, USA) software. Representative regions of interest (ROI) were chosen by a specialized pathologist, and multiple fields of view were acquired at 20× power for further analysis. The multispectral images were analyzed using InForm image analysis software 2.4 (PerkinElmer, Waltham, MA, USA). Density of cells in each ROI was calculated by combining the cell counts from all images and normalizing by the total area (cell/mm²).

2.3. Assessment of Hematological Parameters

Blood samples were routinely collected prior to therapy (Day 0 or 1) and every 7 days. Blood indexes included lymphocytes (L), monocytes (M), platelets (P), and neutrophils (N). We also calculated neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) at the start of immunotherapy. SII was defined as P × N/L. Immune related overall survival (irOS) was defined as the time from initial anti-PD-1/PD-L1 based treatment to death. Immune related progression-free survival (irPFS) was defined as the time from initial anti-PD-1/PD-L1 based treatment to disease progress or death. Censoring occurred if patients were still alive at last follow-up.

2.4. Statistical Analysis

Our primary hypothesis was based on the assessment of an association of blood indexes including NLR, LMR, PLR, and SII at baseline with the immune cell infiltration in primary tumor location. Our second aim was to analyze the blood index-related mortality in a multivariable-adjusted Cox proportional hazards regression model. We initially included the variables of age (<60 vs. ≥60), sex (male vs. female), tumor location (GEJ vs. Non-GJE), Lauren classification (intestinal type vs. diffused type vs. mixed type), lines of therapy (1 vs. 2 vs. ≥3), and types of therapy (immunotherapy alone vs. combination with other therapy). We conducted a backward elimination with a threshold of p = 0.05 to select variables for the final models. For cases with missing information in any of the categorical covariates (tumor location (0.92%), tumor differentiation (7.34%), Lauren classification (6.42%), HER2 expression (9.17%), MMR status (10.09%), PD-L1 expression (11.93%), and EBER status (19.27%)), we included these cases in the majority category of a given covariate. We implemented the Kapan–Meier method to estimate the distribution of irPFS and irOS, and log-rank test into our analyses. All statistical analyses were performed using SPSS (Version 20, Chicago, IL, USA) and software package R (version 4.2.1). Packages of “survival” and “survminer” were used in R analysis. All P values were two-sided, and statistical significance was considered at p < 0.05.
3. Results

3.1. Clinicopathological Features of Gastric Cancer Patients

Eighty patients were enrolled in the first cohort for microenvironment analysis (Table 1). The median age of the patients was 60 years (range, 54–66 years), and the majority of patients were men (76.3%). The clinicopathological features of 357 patients in the validation cohort are also presented in Table 1. Among 357 patients, 45 (12.6%) were dMMR, and 26 (7.3%) were EBV positive, respectively.

Table 1. Baseline characteristics of gastric cancer patients.

| Characteristic * | Total (Test Cohort) | Total (Validation Cohort) |
|------------------|---------------------|---------------------------|
|                  | n = 80              | n = 357                   |
| **Age**          |                     |                           |
| Median, IQR      | 60 (54–66)          | 59 (51–65)                |
| **Sex**          |                     |                           |
| Male             | 61 (76.3%)          | 255 (71.4%)               |
| Female           | 19 (23.7%)          | 102 (28.6%)               |
| **ECOG PS**      |                     |                           |
| 0                | 49 (61.3%)          | 166 (46.5%)               |
| ≥1               | 31 (38.7%)          | 191 (53.5%)               |
| **Location**     |                     |                           |
| GEJ              | 24 (30.0%)          | 112 (31.4%)               |
| Non-GEJ          | 56 (70.0%)          | 245 (68.6%)               |
| **Differentiation** |                 |                           |
| High             | 0 (0%)              | 1 (0.3%)                  |
| Moderate         | 23 (28.8%)          | 88 (24.6%)                |
| Moderate-poor    | 22 (27.5%)          | 62 (17.4%)                |
| Poor             | 35 (43.7%)          | 195 (54.6%)               |
| NA               | 0 (0%)              | 11 (3.1%)                 |
| **Lauren classification** |             |                           |
| Intestinal type  | 38 (47.5%)          | 138 (38.7%)               |
| Diffused type    | 18 (22.5%)          | 89 (24.9%)                |
| Mixed type       | 24 (30.0%)          | 79 (22.1%)                |
| NA               | 0 (0%)              | 51 (14.3%)                |
| **Stage**        |                     |                           |
| I                | 3 (3.8%)            | 1 (0.3%)                  |
| II               | 9 (11.3%)           | 4 (1.1%)                  |
| III              | 29 (36.2%)          | 27 (7.6%)                 |
| IV               | 39 (48.7%)          | 324 (90.7%)               |
| NA               | 0 (0%)              | 1 (0.3%)                  |
| **HER2 expression** |                 |                           |
| Positive         | 22 (27.5%)          | 75 (21.0%)                |
| Negative         | 58 (72.5%)          | 268 (75.1%)               |
| NA               | 0 (0%)              | 14 (3.9%)                 |
| **PD-L1 expression (CPS)** |             |                           |
| ≥10              | 36 (45.0%)          | 88 (24.6%)                |
| 5-10             | 10 (12.5%)          | 31 (8.7%)                 |
| 1-5              | 17 (21.2%)          | 16 (4.5%)                 |
| <1               | 17 (21.2%)          | 96 (26.9%)                |
| NA               | 0 (0%)              | 126 (35.3%)               |
| **MMR status**   |                     |                           |
| pMMR             | 69 (86.25%)         | 266 (74.5%)               |
| dMMR             | 11 (13.75%)         | 45 (12.6%)                |
| NA               | 0 (0%)              | 46 (12.9%)                |
Table 1. Cont.

| Characteristic | Total (Test Cohort) | Total (Validation Cohort) |
|----------------|--------------------|--------------------------|
|                | \( n = 80 \)      | \( n = 357 \)            |
| EBV status     |                    |                          |
| Positive       | 10 (12.5%)         | 26 (7.3%)                |
| Negative       | 70 (87.5%)         | 285 (79.8%)              |
| NA             | 0 (0%)             | 46 (12.9%)               |

*Percentage indicates the proportion of patients with a specific clinical, pathologic, or molecular characteristic among all patients. Abbreviations: dMMR, deficient mismatch repair; pMMR, proficient mismatch repair.

3.2. Blood Indexes Were Associated with Immune Cell Concentrations in Primary Tumor

To investigate the tumor-infiltrating immune cells (TIICs) within GC, we quantified the densities of immune cells in 80 full-face formalin-fixed paraffin-embedded (FFPE) samples with m-IHC staining. Cell phenotyping data were obtained based on positivity and relative intensity of all markers in one panel. Cell population densities were calculated for “all” regions (tumor + stroma) and measured separately in tumor and stroma. TIICs were analyzed at a single-cell level, and 26 major populations were characterized (Figure 1).

![Figure 1](image-url)
The density of exhausted CD8+ T cell was significantly positively correlated with NLR (p = 0.029), PLR (p = 0.007), and SII (p = 0.047). In detail, higher NLR was associated with higher CD8+LAG3−PD1− (p = 0.015), higher CD8+LAG3−PD1− (p = 0.011), higher CD8+LAG3−PD1− (p = 0.039), higher CD8+PD1−TIM3− (p = 0.010), and higher CD8+LAG3−PD1−TIM3− (p = 0.005). Inversely, higher LMR was associated with lower CD8+LAG3−PD1− (p = 0.045), lower CD8+LAG3−PD1− (p = 0.023), lower CD8+PD1−TIM3− (p = 0.031), and lower CD8+LAG3−PD1−TIM3− (p = 0.012). Furthermore, PLR was associated with higher CD8+LAG3−PD1− (p = 0.022), higher CD8+LAG3−PD1− (p = 0.016), higher CD8+LAG3−PD1− (p = 0.014), higher CD8+PD1−TIM3− (p = 0.004), and higher CD8+LAG3−PD1−TIM3− (p = 0.026). SII was associated with higher CD8+LAG3−PD1− (p = 0.029), higher CD8+LAG3−PD1− (p = 0.046), and higher CD8+PD1−TIM3− (p = 0.012). In addition, the density of CD4+ T cells only showed relevance with PLR (p = 0.041), especially in the CD4+FOXP3− group (p = 0.027), whereas the density of CD68+ macrophages in tumor score was associated with PLR (p = 0.004), and SII (p = 0.010), especially in the CD68+CD163− macrophage group (p = 0.001 and p = 0.002, separately), and STING-altered CD68+ macrophages were associated with SII (p = 0.010) (Figure 2, Supplementary Figures S1–S4). We observed the same trends in the tumor core, tumor region and stromal regions (Supplementary Table S2–S4).

3.3. Blood Indexes Predicting Survival in GC Patients Receiving Anti-PD-1/PD-L1 Immunotherapy

We retrospectively included 357 GC patients with available data on baseline blood indexes including neutrophils, monocytes and lymphocytes who received anti-PD-1/PD-L1-based treatments (1st, or 2nd, or 3rd line immunotherapy). We calculated LMR, NLR, PLR, and SII at baseline. Median irPFS and irOS after therapy initiation were 6.6 (95%CI: 5.3–8.4) and 16.3 (95%CI: 13.0–18.8) months, respectively.

We examined the association of NLR, LMR, PLR, and SII at baseline with survival (Tables 2 and 3). In univariate analysis, higher NLR was significantly associated with inferior irOS (p = 0.013, HR = 1.40, 95%CI: 1.10–1.90). Additionally, higher SII was associated with a trend of inferior irOS (p = 0.077, HR = 1.30, 95%CI: 0.97–1.70), and higher LMR with a trend of superior irOS (p = 0.085, HR = 0.78, 95%CI: 0.59–1.00).

Figure 2. The relationship of NLR, LMR, PLR, and SII with the density of tumor infiltrating immune cells in tumor core.
### Table 2. Multivariate analysis of independent risk factors for disease progression.

| Variables   | Progression-Free Survival | Progression-Free Survival |
|-------------|----------------------------|---------------------------|
|             | Hazard Ratio   | p      | Hazard Ratio   | p      |
|             | Multivariate analysis with LMR | Multivariate analysis with Monocytes |
| Lauren      | 1             | 0.013  | 1             | 0.0056 |
| Intestinal  | 1             | 1      | 1             | 1      |
| Diffuse     | 1.65 (1.11–2.45) | 0.69   | 1.77 (1.18–2.64) | 0.84   |
| Peritoneal  | 1             | 1      | 1             | 1      |
| Absent      | 1.09 (0.71–1.68) | 0.026  | 0.96 (0.62–1.47) | 0.0024 |
| Present     |                |        |                |        |
| Line        |                |        |                |        |
| First Line  | 1             | 1      | 1             | 1      |
| Others      | 1.55 (1.05–2.28) | 0.034  | 1.86 (1.25–2.78) | 0.00034 |
| LMR Low     | 1             | 1      | 1             | 1      |
| High NLR    | 0.66 (0.45–0.97) | 1      | 1.82 (1.22–2.71) | 1      |

Furthermore, LMR from baseline was an independent prognostic factor for irPFS in multivariate analysis ($p = 0.034$, adjusted HR = 0.66, 95% CI: 0.45–0.97), and monocytes from baseline were an independent prognostic factor for irPFS in both univariate ($p = 0.015$, HR = 1.50, 95% CI: 1.10–2.00) and multivariate analysis ($p = 0.003$, adjusted HR = 1.82, 95% CI: 1.22–2.71). Figure 3 and Figure S5 show Kaplan–Meier curves for irPFS and irOS according to blood indexes.

### Table 3. Multivariate analysis of NLR for death.

| Variables   | Univariate Analysis | Multivariate Analysis |
|-------------|---------------------|-----------------------|
|             | Hazard Ratio   | p      | Hazard Ratio   | p      |
| Gender      | 1             | 0.003  | 1             | 0.28   |
| Male        | 1             | 1      | 0.68 (0.51–0.9) | 0.60 (0.41–0.88) |
| Female      | 0.63 (0.47–0.86) | <0.001 | 0.85 (0.57–1.29) | 0.0076 |
| Age <60     | 1             | 1      | 0.68 (0.51–0.9) | 0.60 (0.41–0.88) |
| ≥60         | 0.63 (0.47–0.86) | <0.001 | 0.85 (0.57–1.29) | 0.0076 |
| Differentiation | 1    | 0.023  | 1             | 0.25   |
| Moderate    | 1             | 1      | 0.62 (0.32–1.20) | 0.12   |
| Poor        | 1.4 (1–1.9)   | 0.029  | 0.62 (0.32–1.20) | 0.12   |
| HER2        | 1             | 1      | 0.61 (0.36–1.03) | 0.32   |
| Negative    | 0.65 (0.44–0.96) | 0.0021 | 0.61 (0.36–1.03) | 0.32   |
| Positive    | 0.65 (0.44–0.96) | 0.0021 | 0.61 (0.36–1.03) | 0.32   |
| Peritoneal  |                |        |                |        |
| Absent      | 1             | 1      | 0.85 (0.57–1.28) | 0.0091 |
| Present     | 1.6 (1.3–2.1)  | 0.0023 | 0.85 (0.57–1.28) | 0.0091 |
| Stage       |                |        |                |        |
| I/II/III    | 1             | 1      | 3.41 (1.32–8.79) | <0.001 |
| IV          | 3 (1.5–5.9)   | <0.001 | 3.41 (1.32–8.79) | <0.001 |
| Line        |                |        |                |        |
| First Line  | 1             | 1      | 2.60 (1.65–4.09) | 0.17   |
| Others      | 2.6 (1.9–3.5)  |        | 2.60 (1.65–4.09) | 0.17   |
| NLR Low     | 1             | 1      | 1.30 (0.90–1.89) |        |
| High NLR    | 1.4 (1.1–1.9)  | 1      | 1.30 (0.90–1.89) |        |
4. Discussion

We present a detailed multistep platform for multispectral imaging of tissues that generates high-quality datasets at single-cell resolution for biomarker discovery and quantitative pathology to characterize the tumor immune microenvironment and to guide precision immunotherapy in GC. To our knowledge, this is the first study to investigate the association of blood indexes with rare immune cell types including CD8 exhausted T cells in the primary tumor core. In addition, this is also the largest validation cohort of GC receiving anti-PD-1/PD-L1 therapy.

CD8 T cell subsets inform the mechanism of immune checkpoint inhibitors. We adopted a detailed panel of markers providing potential biology of T cells. Conflicting prognostic roles of CD8 T cells have been reported and may be due to patients with higher CD8 T cell densities also having higher PD-L1 expression [13]. In our work, we classified CD8 T cells into precise categories. We found that almost all CD8 T cell categories, regardless of LAG3, PD-1, or TIM3 expression, were associated with NLR, indicating that NLR could act as a specific marker for the density of CD8 T cells in primary tumor. Moreover, we found that PLR was more likely associated with CD8+/PD1− and CD8+/LAG3− subsets, suggesting a potential benefit for the therapeutic population. In addition, M1 macrophages were suggested to be associated with PLR and SII, which may help distinguish immune tolerance and resistance.

Previous reports suggested that CD8 T cells could be induced to gradual deterioration of T cell function by excessive amounts of signals, a state called “exhaustion” [14]. Exhausted T cells express multiple inhibitory receptors, such as PD-1, LAG3, and TIM3 [15]. Targeting PD-1 together with LAG3 facilitates T cell reinvigoration [16]. Our study found a subset of pre-exhausted T cells that could be distinguished at baseline, suggesting single anti-PD-1 therapy might be effective in initial treatment [17]. Additionally, monitoring blood indexes would let us know when to add combination therapy as exhausted cells appear and proliferate [18]. Hsu and colleagues found that exhausted CD8+/LAG3+ T cells could predict efficacy of single-agent immunotherapy versus immunotherapy combination therapies in hepatocellular carcinoma. Due to the small population, no significant difference was achieved, but the trend preferred combination immunotherapies [19]. Large-scale evidence is needed.

This study offers new insights into the nature of GC immunity and how this information can be harnessed towards effective immunotherapy strategies. From our study, we learned that GC cells have a population that can benefit from immunotherapy using anti-PD-1 alone, suggesting a potential reason for CheckMate649 to succeed with 60% ORR [3]. It will be interesting and cost-effective to see a variety of patterns of blood indexes before treatment, which can predict different responses. Combination of immunotherapy, such as antibody against PD-1/PD-L1 with antibody against LAG3, TIM3, or CTLA4, could further
increase tumor-infiltrating lymphocyte functions [20]. This provides a way to reverse the remaining 40% of primary resistance and large amount of acquired resistance in GC.

Our study has several limitations. Immune cell subsets can be related to one another, as “daughter cells” with distinct phenotypes are derived from the same “ancestor cell”. Thus, independent studies are warranted to confirm our findings. The strengths of the study include the acquisition of the entire TME in the whole slides, followed by standardized selection of discrete ROIs. These findings highlight the benefit of using blood indexes in the context of their relation with primary tumor. While our results support the prognostic significance of blood indexes in gastric cancer, further investigations are required to confirm the findings.

5. Conclusions

Our results support blood indexes as a robust, quantitative prognostic and predictive tool in gastric cancer. The exploration of the microenvironment composition of gastric cancer samples would offer critical insights into the complex and heterogeneous immune landscape associated with blood indexes and immunotherapy survival.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers14153608/s1, Figure S1: The relationship of NLR with the density of immune cells in tumor core; Figure S2: The relationship of LMR with the density of immune cells in tumor core; Figure S3: The relationship of PLR with the density of immune cells in tumor core; Figure S4: The relationship of SII with the density of immune cells in tumor core; Figure S5: Kaplan–Meier curves for progression-free survival and overall survival according to blood indexes; Table S1: Antibodies used for m-IHC; Table S2: Association between immune markers and immune cell density in the tumor microenvironment of tumor core; Table S3: Association between immune markers and immune cell density in the tumor microenvironment in tumor region; Table S4: Association between immune markers and immune cell density in the tumor microenvironment in stromal region.

Author Contributions: Conceptualization, Y.C. and Y.L. (Yilin Li); methodology, Q.Y.; software, J.Y.; validation, Y.L. (Yanyan Li) and X.Z.; formal analysis, J.Y.; investigation, Y.C.; resources, Y.L. (Yilin Li); data curation, Y.L. (Yanyan Li) and L.J.; writing—original draft preparation, J.Y. and X.F.; writing—review and editing, Y.C.; visualization, Y.L. (Yilin Li) and L.S.; supervision, Y.L. (Yilin Li); project administration, Y.C.; funding acquisition, Y.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Major Program of National Natural Science Foundation of China, grant number 91959205 (L.S.); the Beijing Natural Science Foundation, grant number 7222021 (Y.C.); and Wu Jieping Medical Foundation, grant number 320.6750.2021-02-15 (Y.C.).

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Peking University Cancer Hospital (protocol code 2020KT08).

Informed Consent Statement: The Institutional Review Board of Peking University Cancer Hospital waived the requirement of written informed consent due to the retrospective design of this study.

Data Availability Statement: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Acknowledgments: The authors thank Lei Jiao, Jie Ma, Xiaojiao Hao, Pengxiang Li (Panovue Biotechnology (Beijing) Co., Ltd.) for providing technical assistance.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef] [PubMed]
2. Joshi, S.S.; Badgwell, B.D. Current treatment and recent progress in gastric cancer. CA Cancer J. Clin. 2021, 71, 264–279. [CrossRef] [PubMed]
3. Janjigian, Y.Y.; Shitara, K.; Moehler, M.; Garrido, M.; Salman, P.; Shen, L.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Campos Bragagnoli, A.; et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 2021, 398, 27–40. [CrossRef]

4. Xie, T.; Zhang, Z.; Zhang, X.; Qi, C.; Shen, L.; Peng, Z. Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis. Front. Oncol. 2021, 11, 646355. [CrossRef] [PubMed]

5. Bagaev, A.; Kotlov, N.; Nomie, K.; Svekolkin, V.; Gafurov, A.; Isaeva, O.; Osokin, N.; Kozlov, I.; Frenkel, F.; Gancharova, O.; et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021, 39, 845–865 e847. [CrossRef] [PubMed]

6. Yarchoan, M.; Xing, D.; Luan, L.; Xu, H.; Sharma, R.B.; Popovic, A.; Pawlik, T.M.; Kim, A.K.; Zhu, Q.; Jaffee, E.M.; et al. Characterization of the Immune Microenvironment in Hepatocellular Carcinoma. Clin. Cancer Res. 2017, 23, 7333–7339. [CrossRef] [PubMed]

7. Paver, E.C.; Cooper, W.A.; Colebatch, A.J.; Ferguson, P.M.; Hill, S.K.; Lum, T.; Shin, J.S.; O’Toole, S.; Anderson, L.; Sloyer, R.A.; et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: A guide to immunohistochemistry implementation and interpretation. Pathology 2021, 53, 141–156. [CrossRef] [PubMed]

8. Hu, B.S.; Tang, T.; Jia, J.L.; Xie, B.C.; Wu, T.L.; Sheng, Y.Y.; Xue, Y.Z.; Tang, H.M. CD137 agonist induces gastric cancer cell apoptosis by enhancing the functions of CD8(+) T cells via NF-kappaB signaling. Cancer Cell. Int. 2020, 20, 513. [CrossRef] [PubMed]

9. Xia, S.; Gu, Y.; Zhang, H.; Fei, Y.; Cao, Y.; Fang, H.; Wang, J.; Lin, C.; Zhang, H.; Li, H.; et al. Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer. Oncoimmunology 2021, 10, 197586. [CrossRef] [PubMed]

10. Tan, W.C.C.; Nerurkar, S.N.; Cai, H.Y.; Ng, H.H.M.; Wu, D.; Wee, Y.T.F.; Lim, J.C.T.; Yeong, J.; Lim, T.K.H. Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Commun. 2020, 40, 135–153. [CrossRef] [PubMed]

11. Liu, C.; Wang, Y.; Li, S.; Jiao, X.; Zou, J.; Wang, Z.; Qi, C.; Zhang, X.; Li, J.; Lu, Z.; et al. Early change in peripheral CD4(+) T cells associated with clinical outcomes of immunotherapy in gastrointestinal cancer. Immunochemistry 2021, 13, 55–66. [CrossRef] [PubMed]

12. Chen, Y.; Zhang, C.; Peng, Z.; Qi, C.; Gong, J.; Zhang, X.; Li, J.; Shen, L. Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor. Front. Oncol. 2021, 11, 589022. [CrossRef] [PubMed]

13. Thompson, E.D.; Zahurak, M.; Murphy, A.; Cornish, T.; Cuka, N.; Abdelfatah, E.; Yang, S.; Duncan, M.; Ahuja, N.; Taube, J.M.; et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut 2017, 66, 794–801. [CrossRef] [PubMed]

14. Dolina, J.S.; Van Braeckel-Budimir, N.; Thomas, G.D.; Salek-Ardakani, S. CD8(+) T Cell Exhaustion in Cancer. Front. Immunol. 2021, 12, 715234. [CrossRef] [PubMed]

15. Kurachi, M. CD8(+) T cell exhaustion. Semin. Immunopathol. 2019, 41, 327–337. [CrossRef] [PubMed]

16. Ruffo, E.; Wu, R.C.; Bruno, T.C.; Workman, C.J.; Vignali, D.A.A. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. Semin. Immunol. 2019, 42, 101305. [CrossRef] [PubMed]

17. Ando, M.; Ito, M.; Srirat, T.; Kondo, T.; Yoshimura, A. Memory T cell, exhaustion, and tumor immunity. Immunol. Med. 2020, 43, 1–9. [CrossRef]

18. Bassez, A.; Vos, H.; Van Dyck, L.; Floris, G.; Arijs, I.; Desmedt, C.; Beeckx, B.; Vanden Bempt, M.; Nevelsteen, I.; Lambein, K.; et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat. Med. 2021, 27, 820–832. [CrossRef] [PubMed]

19. Hsu, C.L.; Ou, D.L.; Bai, L.Y.; Chen, C.W.; Lin, L.; Huang, S.F.; Cheng, A.L.; Jeng, Y.M.; Hsu, C. Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Liver Cancer 2021, 10, 346–359. [CrossRef] [PubMed]

20. Zhou, G.; Sprengers, D.; Boor, P.P.C.; Doukas, M.; Schutz, H.; Mancham, S.; Pedroza-Gonzalez, A.; Polak, W.G.; de Jonge, J.; Gaspersz, M.; et al. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Gastroenterology 2017, 153, 1107–1119 e1110. [CrossRef] [PubMed]